High-Risk Factors and Therapeutic Advances in Ovarian Cancer

Among gynecologic malignancies, ovarian cancer is the most lethal, primarily due to its insidious early symptoms, lack of effective screening methods, and high risk of recurrence. It poses substantial challenges to clinical diagnosis and treatment. In recent years, the clinical application of poly A...

Full description

Saved in:
Bibliographic Details
Published inZhongliu fangzhi yanjiu Vol. 52; no. 7; pp. 637 - 644
Main Authors Sha, Xiaoyu, Zuo, Weiwei, Gan, Jing, Liu, Yankun
Format Journal Article
LanguageChinese
English
Published Tianjin China Anti-Cancer Association 2025
Magazine House of Cancer Research on Prevention and Treatment
Subjects
brca1/2
Cancer
genetic testing
Malignancy
Ovarian cancer
parp inhibitors
Ribose
Risk factors
treatment
Online AccessGet full text

Cover

More Information
Summary:Among gynecologic malignancies, ovarian cancer is the most lethal, primarily due to its insidious early symptoms, lack of effective screening methods, and high risk of recurrence. It poses substantial challenges to clinical diagnosis and treatment. In recent years, the clinical application of poly ADP-ribose polymerase inhibitors has promoted a comprehensive management model that integrates targeted therapy with conventional treatments. This review, aiming to provide new perspectives and approaches for future research, summarizes the high-risk factors and first-line treatment strategies for ovarian cancer. Further studies should focus on optimizing personalized treatment strategies and exploring novel targeted therapies to improve patient survival outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:1000-8578
DOI:10.3971/j.issn.1000-8578.2025.24.1243